Treatment of Small Cell Bronchogenic Carcinoma with VM-26
Overview
Authors
Affiliations
VM-26 is active in small cell bronchogenic carcinoma even in patients resistant to previous chemotherapy. The overall response rate was 28%, with a response rate of 29% in patients resistant to previous chemotherapy. This response rate is similar to that obtained with other single agents including Adriamycin, vincristine, cyclophosphamide, and procarbazine. The mild subjective and objective toxic effects of the drug make it a potentially useful agent in the treatment of this tumor.
Teniposide: overview of its therapeutic potential in adult cancers.
Muggia F Cancer Chemother Pharmacol. 1994; 34 Suppl:S127-33.
PMID: 8070021 DOI: 10.1007/BF00684876.
Current development of podophyllotoxins.
Canetta R, Hilgard P, Florentine S, Bedogni P, Lenaz L Cancer Chemother Pharmacol. 1982; 7(2-3):93-8.
PMID: 7044596 DOI: 10.1007/BF00254528.
Macbeth F Cancer Chemother Pharmacol. 1982; 7(2-3):87-91.
PMID: 7044595 DOI: 10.1007/BF00254527.
The podophyllotoxin derivatives VP16-213 and VM26.
Issell B Cancer Chemother Pharmacol. 1982; 7(2-3):73-80.
PMID: 7044593 DOI: 10.1007/BF00254525.
VM-26 in colorectal carcinoma: a Southwest Oncology Group study.
Oishi N, Fleming T, Laufman L, Ungerleider J, Natale R, Einstein Jr A Invest New Drugs. 1990; 8(1):93-5.
PMID: 2188930 DOI: 10.1007/BF00216931.